Persistence with stroke prevention medications 3 months after hospitalization

Cheryl D. Bushnell, Louise O. Zimmer, Wenqin Pan, Dai Wai M. Olson, Xin Zhao, Tatiana Meteleva, Lee Schwamm, Bruce Ovbiagele, Linda Williams, Kenneth A. LaBresh, Eric D. Peterson

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Objective: To measure longitudinal use of stroke prevention medications following stroke hospital discharge. We hypothesized that a combination of patient-, provider-, and system-level factors influence medication-taking behavior. Design: Observational cohort design. Setting: One hundred six US hospitals participating in the American Heart Association Get With The Guidelines - Stroke program. Patients: Two thousand eight hundred eighty-eight patients 18 years or older admitted with ischemic stroke or transient ischemic attack. Main Outcome Measure: Regimen persistence, including use of antiplatelet therapies, warfarin, antihypertensive therapies, lipid-lowering therapies, or diabetes medications, from discharge to 3 months. Reasons for nonpersistence were also ascertained. Results: Two thousand five hundred ninety-eight patients (90.0%) were eligible for analysis. At 3 months, 75.5% of subjects continued taking all secondary prevention-medications prescribed at discharge. Persistence at 3 months was associated with decreasing number of medication classes prescribed, increasing age,medical history, less severe stroke disability, having insurance, working status, understanding why medications are prescribed and how to refill them, increased quality of life, financial hardship, geographic region, and hospital size. Conclusions: One-quarter of stroke patients reported discontinuing 1 or more of their prescribed regimen of secondary prevention medications within 3 months of hospitalization for an acute stroke. Several modifiable factors associated with regimen persistence were identified and could be targets for improving long-term secondary stroke prevention.

Original languageEnglish (US)
Pages (from-to)1456-1463
Number of pages8
JournalArchives of Neurology
Volume67
Issue number12
DOIs
StatePublished - Dec 1 2010

Fingerprint

Hospitalization
Stroke
Secondary Prevention
Disability Insurance
Health Facility Size
Insurance Coverage
Persistence
Medication
Transient Ischemic Attack
Warfarin
Antihypertensive Agents
Therapeutics
Quality of Life
Outcome Assessment (Health Care)
Guidelines
Lipids
Therapy

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Bushnell, C. D., Zimmer, L. O., Pan, W., Olson, D. W. M., Zhao, X., Meteleva, T., ... Peterson, E. D. (2010). Persistence with stroke prevention medications 3 months after hospitalization. Archives of Neurology, 67(12), 1456-1463. https://doi.org/10.1001/archneurol.2010.190

Persistence with stroke prevention medications 3 months after hospitalization. / Bushnell, Cheryl D.; Zimmer, Louise O.; Pan, Wenqin; Olson, Dai Wai M.; Zhao, Xin; Meteleva, Tatiana; Schwamm, Lee; Ovbiagele, Bruce; Williams, Linda; LaBresh, Kenneth A.; Peterson, Eric D.

In: Archives of Neurology, Vol. 67, No. 12, 01.12.2010, p. 1456-1463.

Research output: Contribution to journalArticle

Bushnell, CD, Zimmer, LO, Pan, W, Olson, DWM, Zhao, X, Meteleva, T, Schwamm, L, Ovbiagele, B, Williams, L, LaBresh, KA & Peterson, ED 2010, 'Persistence with stroke prevention medications 3 months after hospitalization', Archives of Neurology, vol. 67, no. 12, pp. 1456-1463. https://doi.org/10.1001/archneurol.2010.190
Bushnell CD, Zimmer LO, Pan W, Olson DWM, Zhao X, Meteleva T et al. Persistence with stroke prevention medications 3 months after hospitalization. Archives of Neurology. 2010 Dec 1;67(12):1456-1463. https://doi.org/10.1001/archneurol.2010.190
Bushnell, Cheryl D. ; Zimmer, Louise O. ; Pan, Wenqin ; Olson, Dai Wai M. ; Zhao, Xin ; Meteleva, Tatiana ; Schwamm, Lee ; Ovbiagele, Bruce ; Williams, Linda ; LaBresh, Kenneth A. ; Peterson, Eric D. / Persistence with stroke prevention medications 3 months after hospitalization. In: Archives of Neurology. 2010 ; Vol. 67, No. 12. pp. 1456-1463.
@article{252d987ae68946a183adbfb7f1bc3cdf,
title = "Persistence with stroke prevention medications 3 months after hospitalization",
abstract = "Objective: To measure longitudinal use of stroke prevention medications following stroke hospital discharge. We hypothesized that a combination of patient-, provider-, and system-level factors influence medication-taking behavior. Design: Observational cohort design. Setting: One hundred six US hospitals participating in the American Heart Association Get With The Guidelines - Stroke program. Patients: Two thousand eight hundred eighty-eight patients 18 years or older admitted with ischemic stroke or transient ischemic attack. Main Outcome Measure: Regimen persistence, including use of antiplatelet therapies, warfarin, antihypertensive therapies, lipid-lowering therapies, or diabetes medications, from discharge to 3 months. Reasons for nonpersistence were also ascertained. Results: Two thousand five hundred ninety-eight patients (90.0{\%}) were eligible for analysis. At 3 months, 75.5{\%} of subjects continued taking all secondary prevention-medications prescribed at discharge. Persistence at 3 months was associated with decreasing number of medication classes prescribed, increasing age,medical history, less severe stroke disability, having insurance, working status, understanding why medications are prescribed and how to refill them, increased quality of life, financial hardship, geographic region, and hospital size. Conclusions: One-quarter of stroke patients reported discontinuing 1 or more of their prescribed regimen of secondary prevention medications within 3 months of hospitalization for an acute stroke. Several modifiable factors associated with regimen persistence were identified and could be targets for improving long-term secondary stroke prevention.",
author = "Bushnell, {Cheryl D.} and Zimmer, {Louise O.} and Wenqin Pan and Olson, {Dai Wai M.} and Xin Zhao and Tatiana Meteleva and Lee Schwamm and Bruce Ovbiagele and Linda Williams and LaBresh, {Kenneth A.} and Peterson, {Eric D.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1001/archneurol.2010.190",
language = "English (US)",
volume = "67",
pages = "1456--1463",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Persistence with stroke prevention medications 3 months after hospitalization

AU - Bushnell, Cheryl D.

AU - Zimmer, Louise O.

AU - Pan, Wenqin

AU - Olson, Dai Wai M.

AU - Zhao, Xin

AU - Meteleva, Tatiana

AU - Schwamm, Lee

AU - Ovbiagele, Bruce

AU - Williams, Linda

AU - LaBresh, Kenneth A.

AU - Peterson, Eric D.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Objective: To measure longitudinal use of stroke prevention medications following stroke hospital discharge. We hypothesized that a combination of patient-, provider-, and system-level factors influence medication-taking behavior. Design: Observational cohort design. Setting: One hundred six US hospitals participating in the American Heart Association Get With The Guidelines - Stroke program. Patients: Two thousand eight hundred eighty-eight patients 18 years or older admitted with ischemic stroke or transient ischemic attack. Main Outcome Measure: Regimen persistence, including use of antiplatelet therapies, warfarin, antihypertensive therapies, lipid-lowering therapies, or diabetes medications, from discharge to 3 months. Reasons for nonpersistence were also ascertained. Results: Two thousand five hundred ninety-eight patients (90.0%) were eligible for analysis. At 3 months, 75.5% of subjects continued taking all secondary prevention-medications prescribed at discharge. Persistence at 3 months was associated with decreasing number of medication classes prescribed, increasing age,medical history, less severe stroke disability, having insurance, working status, understanding why medications are prescribed and how to refill them, increased quality of life, financial hardship, geographic region, and hospital size. Conclusions: One-quarter of stroke patients reported discontinuing 1 or more of their prescribed regimen of secondary prevention medications within 3 months of hospitalization for an acute stroke. Several modifiable factors associated with regimen persistence were identified and could be targets for improving long-term secondary stroke prevention.

AB - Objective: To measure longitudinal use of stroke prevention medications following stroke hospital discharge. We hypothesized that a combination of patient-, provider-, and system-level factors influence medication-taking behavior. Design: Observational cohort design. Setting: One hundred six US hospitals participating in the American Heart Association Get With The Guidelines - Stroke program. Patients: Two thousand eight hundred eighty-eight patients 18 years or older admitted with ischemic stroke or transient ischemic attack. Main Outcome Measure: Regimen persistence, including use of antiplatelet therapies, warfarin, antihypertensive therapies, lipid-lowering therapies, or diabetes medications, from discharge to 3 months. Reasons for nonpersistence were also ascertained. Results: Two thousand five hundred ninety-eight patients (90.0%) were eligible for analysis. At 3 months, 75.5% of subjects continued taking all secondary prevention-medications prescribed at discharge. Persistence at 3 months was associated with decreasing number of medication classes prescribed, increasing age,medical history, less severe stroke disability, having insurance, working status, understanding why medications are prescribed and how to refill them, increased quality of life, financial hardship, geographic region, and hospital size. Conclusions: One-quarter of stroke patients reported discontinuing 1 or more of their prescribed regimen of secondary prevention medications within 3 months of hospitalization for an acute stroke. Several modifiable factors associated with regimen persistence were identified and could be targets for improving long-term secondary stroke prevention.

UR - http://www.scopus.com/inward/record.url?scp=78650144757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650144757&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2010.190

DO - 10.1001/archneurol.2010.190

M3 - Article

C2 - 20697032

AN - SCOPUS:78650144757

VL - 67

SP - 1456

EP - 1463

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 12

ER -